^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD8 positive

i
Other names: CD8, CD8A, cluster of differentiation 8, CD8a Molecule, T-Cell Surface Glycoprotein CD8 Alpha Chain, T-Lymphocyte Differentiation Antigen T8/Leu-2, CD8 Antigen, Alpha Polypeptide (P32), Leu2 T-Lymphocyte Antigen, OKT8 T-Cell Antigen, T-Cell Antigen Leu2, T Cell Co-Receptor, T8 T-Cell Antigen, CD8a Antigen
Entrez ID:
Related biomarkers:
Related tests:
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/05/2024
Initiation :
02/17/2021
Primary completion :
07/31/2024
Completion :
07/31/2024
PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3
|
PD-L1 expression • PD-1 expression • CD8 positive • CD47 expression
|
Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)
Phase 2
Roswell Park Cancer Institute
Recruiting
Last update posted :
05/30/2024
Initiation :
06/20/2024
Primary completion :
08/22/2025
Completion :
08/22/2025
CD8
|
CD8 positive
|
Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
Phase 2
University of Texas Southwestern Medical Center
Recruiting
Last update posted :
05/20/2024
Initiation :
04/15/2021
Primary completion :
04/15/2026
Completion :
04/15/2028
HER-2 • ER • PGR • CD8
|
HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive
|
Verzenio (abemaciclib) • letrozole
Phase 1
Bristol-Myers Squibb
Completed
Last update posted :
04/23/2024
Initiation :
09/27/2012
Primary completion :
09/12/2017
Completion :
10/25/2018
CD8 • IFNG • CXCL10 • CXCL9 • CD4
|
CD8 positive • CD4 positive
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
04/04/2024
Initiation :
08/12/2021
Primary completion :
08/01/2025
Completion :
08/01/2025
CD8
|
CD8 positive
|
Jakafi (ruxolitinib) • Copiktra (duvelisib)
Phase 2
Robert L. Ferris, MD, PhD
Recruiting
Last update posted :
01/11/2024
Initiation :
01/08/2020
Primary completion :
05/31/2027
Completion :
09/30/2027
TMB • LAG3
|
CD8 positive
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
Phase 4
University of Maryland, Baltimore
Active, not recruiting
Last update posted :
12/07/2023
Initiation :
10/24/2013
Primary completion :
06/30/2024
Completion :
06/30/2024
CD8 • IFNG • TNFA
|
CD8 positive
Phase N/A
NYU Langone Health
Recruiting
Last update posted :
11/09/2023
Initiation :
11/15/2022
Primary completion :
03/01/2024
Completion :
09/01/2024
CD8 • GZMB
|
CD8 expression • CD8 positive
Phase 2
Inovio Pharmaceuticals
Completed
Last update posted :
07/14/2023
Initiation :
05/15/2018
Primary completion :
06/16/2020
Completion :
05/26/2021
CD8 • TNFRSF9
|
CD8 positive
|
bizalimogene ralaplasmid (VGX-3100)
Phase 3
Pfizer
Completed
Last update posted :
07/10/2023
Initiation :
12/21/2015
Primary completion :
09/19/2018
Completion :
07/12/2022
PD-L1 • CD8
|
PD-L1 expression • CD8 positive
|
Bavencio (avelumab) • pegylated liposomal doxorubicin • doxorubicin liposomal
Phase 2
CCTU- Cancer Theme
Recruiting
Last update posted :
06/07/2023
Initiation :
07/27/2020
Primary completion :
11/30/2025
Completion :
11/30/2025
CD8 • IL2
|
CD8 positive
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
Phase 1/2
University Hospital, Antwerp
Completed
Last update posted :
05/12/2023
Initiation :
05/03/2010
Primary completion :
04/25/2016
Completion :
05/05/2018
HER-2 • KRAS • PGR • CD8 • WT1
|
HER-2 negative • RAS wild-type • CD8 positive
Phase 2
Zealand University Hospital
Completed
Last update posted :
03/03/2022
Initiation :
07/10/2018
Primary completion :
09/02/2021
Completion :
10/04/2021
CD8 • CASP3
|
CD8 positive
|
metformin
Phase 2
Sichuan Cancer Hospital and Research Institute
Recruiting
Last update posted :
09/15/2021
Initiation :
04/01/2021
Primary completion :
04/01/2022
Completion :
03/31/2023
CD8
|
CD8 positive
|
carboplatin • paclitaxel
Phase 1/2
Fukushima Medical University
Unknown status
Last update posted :
07/15/2020
Initiation :
03/28/2018
Primary completion :
01/14/2021
Completion :
02/28/2021
PD-L1 • CD8
|
PD-L1 expression • CD8 positive
|
Opdivo (nivolumab)
Phase 2
UNC Lineberger Comprehensive Cancer Center
Completed
Last update posted :
09/12/2018
Initiation :
12/01/2005
Primary completion :
02/01/2013
Completion :
10/27/2017
HER-2 • CD8 • IFNG
|
HER-2 expression • CD8 positive
|
Herceptin (trastuzumab) • vinorelbine tartrate • Leukine (sargramostim)
Phase 1
University Health Network, Toronto
Withdrawn
Last update posted :
12/29/2017
Initiation :
10/10/2017
Primary completion :
12/21/2017
Completion :
12/21/2017
PD-L1 • CD8 • CD4
|
CD8 positive
|
Imfinzi (durvalumab) • mocetinostat (MGCD0103)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
01/26/2015
Initiation :
10/01/2002
Primary completion :
09/01/2013
Completion :
09/01/2013
CD8
|
CD8 positive